1.1 Articolo in rivista

1.1 Articolo in rivista: [38799] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 4.601 a 4.620 di 38.799

Editorial: Editor's challenge: Dr. Luciano Mutti - what is the true impact of ICIs on survival in the treatment of thoracic malignancies?

2023-01-01 Mutti, L.; Gray, S. G.

Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma

2012-01-01 Jennings, C. J.; O'Grady, A.; Cummins, R.; Murer, B.; Al-Alawi, M.; Madden, S. F.; Mutti, L.; Harvey, B. J.; Thomas, W.; Kay, E. W.

Epigallocatechin-3-gallate induces mesothelioma cell death via H2O2-dependent T-type Ca2+ channel opening

2012-01-01 Ranzato, E.; Martinotti, S.; Magnelli, V.; Murer, B.; Biffo, S.; Mutti, L.; Burlando, B.

PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1

2013-01-01 Pinton, G.; Manente, A. G.; Murer, B.; De Marino, E.; Mutti, L.; Moro, L.

“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013

2015-01-01 Maio, M.; Nicolay, H. J. M.; Cutaia, O.; Fonsatti, E.; Parmiani, G.; Trajanoski, Z.; Sahin, U.; Dellabona, R.; Jachetti, E.; Maccalli, C.; Adelchi Ruffini, P.; Bellone, M.; Fontana, R.; Bondanza, A.; Parmiani, G.; Pellegata, S.; Allavena, P.; Castelli, C.; Santinami, M.; Valmori, D.; Malanchi, I.; De Maria, R.; Moschella, F.; Paga, C.; Bellati, F.; Camerini, R.; Sistigu, A.; Aurisicchio, L.; Bronte, V.; Seliger, B.; Venanzi, F. M.; Hawkins, R.; Dotti, G.; Sangiolo, D.; Covre, A.; Di Giacomo, A. M.; Calabro, L.; Weber, J.; Sznol, M.; Melero, I.; Hannani, D.; de Rosa, F.; Spagnolo, F.; Filaci, G.; Simeone, E.; Ferrone, S.; Marincola, F. M.; Fridman, W. H.; Pawelec, G.; Cavalieri, D.; Mutti, L.; Ceresoli, G.; Ruffini, P. A.; Danielli, R.

Tremelimumab for the treatment of malignant mesothelioma

2015-01-01 Guazzelli, A.; Hussain, M.; Krstic-Demonacos, M.; Mutti, L.

The role of microenvironment and immunity in drug response in leukemia

2016-01-01 Bakker, E.; Qattan, M.; Mutti, L.; Demonacos, C.; Krstic-Demonacos, M.

A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people

2014-01-01 Garritano, S.; De Santi, C.; Silvestri, R.; Melaiu, O.; Cipollini, M.; Barone, E.; Lucchi, M.; Barale, R.; Mutti, L.; Gemignani, F.; Bonotti, A.; Foddis, R.; Cristaudo, A.; Landi, S.

Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study

2021-01-01 Moretti, G.; Aretini, P.; Lessi, F.; Mazzanti, C. M.; Ak, G.; Metintas, M.; Lando, C.; Filiberti, R. A.; Lucchi, M.; Bonotti, A.; Foddis, R.; Cristaudo, A.; Bottari, A.; Apollo, A.; Del Re, M.; Danesi, R.; Mutti, L.; Gemignani, F.; Landi, S.

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism

2017-01-01 De Santi, C.; Melaiu, O.; Bonotti, A.; Cascione, L.; Di Leva, G.; Foddis, R.; Cristaudo, A.; Lucchi, M.; Mora, M.; Truini, A.; Tironi, A.; Murer, B.; Boldorini, R.; Cipollini, M.; Gemignani, F.; Gasparini, P.; Mutti, L.; Landi, S.

Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma

2012-01-01 Pinton, G.; Manente, A. G.; Angeli, G.; Mutti, L.; Moro, L.

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma (PLoS ONE (2017) 12:6 (e0180317) DOI: 10.1371/journal.pone.0085935)

2017-01-01 Melaiu, O.; Stebbing, J.; Lombardo, Y.; Bracci, E.; Uehara, N.; Bonotti, A.; Cristaudo, A.; Foddis, R.; Mutti, L.; Barale, R.; Gemignani, F.; Giamas, G.; Landi, S.

Evaluation of the role of p53 tumour suppressor posttranslational modifications and ttc5cofactor in lung cancer

2021-01-01 Alhebshi, H.; Tian, K.; Patnaik, L.; Taylor, R.; Bezecny, P.; Hall, C.; Muller, P. A. J.; Safari, N.; Creamer, D. P. M.; Demonacos, C.; Mutti, L.; Bittar, M. N.; Krstic-demonacos, M.

The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells

2017-01-01 Pattarozzi, A.; Carra, E.; Favoni, R. E.; Wurth, R.; Marubbi, D.; Filiberti, R. A.; Mutti, L.; Florio, T.; Barbieri, F.; Daga, A.

BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment

2019-01-01 Guazzelli, A.; Meysami, P.; Bakker, E.; Demonacos, C.; Giordano, A.; Krstic-Demonacos, M.; Mutti, L.

Targeting hypoxic response for cancer therapy

2016-01-01 Paolicchi, E.; Gemignani, F.; Krstic-Demonacos, M.; Dedhar, S.; Mutti, L.; Landi, S.

Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo

2013-01-01 Manente, A. G.; Valenti, D.; Pinton, G.; Jithesh, P. V.; Daga, A.; Rossi, L.; Gray, S. G.; O'Byrne, K. J.; Fennell, D. A.; Vacca, R. A.; Nilsson, S.; Mutti, L.; Moro, L.

Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals

2017-01-01 De Santi, C.; Pucci, P.; Bonotti, A.; Melaiu, O.; Cipollini, M.; Silvestri, R.; Vymetalkova, V.; Barone, E.; Paolicchi, E.; Corrado, A.; Lepori, I.; Dell'Anno, I.; Pelle, L.; Vodicka, P.; Mutti, L.; Foddis, R.; Cristaudo, A.; Gemignani, F.; Landi, S.

The biochemical role of the human NEIL1 and NEIL3 DNA glycosylases on model DNA replication forks

2019-01-01 Albelazi, M. S.; Martin, P. R.; Mohammed, S.; Mutti, L.; Parsons, J. L.; Elder, R. H.

Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state

2020-01-01 Alhammad, R.; Khunchai, S.; Tongmuang, N.; Limjindaporn, T.; Yenchitsomanus, P. -T.; Mutti, L.; Krstic-Demonacos, M.; Demonacos, C.

Titolo	Data di pubblicazione	Autore(i)
Editorial: Editor's challenge: Dr. Luciano Mutti - what is the true impact of ICIs on survival in the treatment of thoracic malignancies?	1-gen-2023	Mutti, L.; Gray, S. G.
Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma	1-gen-2012	Jennings, C. J.; O'Grady, A.; Cummins, R.; Murer, B.; Al-Alawi, M.; Madden, S. F.; Mutti, L.; Harvey, B. J.; Thomas, W.; Kay, E. W.
Epigallocatechin-3-gallate induces mesothelioma cell death via H2O2-dependent T-type Ca2+ channel opening	1-gen-2012	Ranzato, E.; Martinotti, S.; Magnelli, V.; Murer, B.; Biffo, S.; Mutti, L.; Burlando, B.
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1	1-gen-2013	Pinton, G.; Manente, A. G.; Murer, B.; De Marino, E.; Mutti, L.; Moro, L.
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013	1-gen-2015	Maio, M.; Nicolay, H. J. M.; Cutaia, O.; Fonsatti, E.; Parmiani, G.; Trajanoski, Z.; Sahin, U.; Dellabona, R.; Jachetti, E.; Maccalli, C.; Adelchi Ruffini, P.; Bellone, M.; Fontana, R.; Bondanza, A.; Parmiani, G.; Pellegata, S.; Allavena, P.; Castelli, C.; Santinami, M.; Valmori, D.; Malanchi, I.; De Maria, R.; Moschella, F.; Paga, C.; Bellati, F.; Camerini, R.; Sistigu, A.; Aurisicchio, L.; Bronte, V.; Seliger, B.; Venanzi, F. M.; Hawkins, R.; Dotti, G.; Sangiolo, D.; Covre, A.; Di Giacomo, A. M.; Calabro, L.; Weber, J.; Sznol, M.; Melero, I.; Hannani, D.; de Rosa, F.; Spagnolo, F.; Filaci, G.; Simeone, E.; Ferrone, S.; Marincola, F. M.; Fridman, W. H.; Pawelec, G.; Cavalieri, D.; Mutti, L.; Ceresoli, G.; Ruffini, P. A.; Danielli, R.
Tremelimumab for the treatment of malignant mesothelioma	1-gen-2015	Guazzelli, A.; Hussain, M.; Krstic-Demonacos, M.; Mutti, L.
The role of microenvironment and immunity in drug response in leukemia	1-gen-2016	Bakker, E.; Qattan, M.; Mutti, L.; Demonacos, C.; Krstic-Demonacos, M.
A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people	1-gen-2014	Garritano, S.; De Santi, C.; Silvestri, R.; Melaiu, O.; Cipollini, M.; Barone, E.; Lucchi, M.; Barale, R.; Mutti, L.; Gemignani, F.; Bonotti, A.; Foddis, R.; Cristaudo, A.; Landi, S.
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study	1-gen-2021	Moretti, G.; Aretini, P.; Lessi, F.; Mazzanti, C. M.; Ak, G.; Metintas, M.; Lando, C.; Filiberti, R. A.; Lucchi, M.; Bonotti, A.; Foddis, R.; Cristaudo, A.; Bottari, A.; Apollo, A.; Del Re, M.; Danesi, R.; Mutti, L.; Gemignani, F.; Landi, S.
Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism	1-gen-2017	De Santi, C.; Melaiu, O.; Bonotti, A.; Cascione, L.; Di Leva, G.; Foddis, R.; Cristaudo, A.; Lucchi, M.; Mora, M.; Truini, A.; Tironi, A.; Murer, B.; Boldorini, R.; Cipollini, M.; Gemignani, F.; Gasparini, P.; Mutti, L.; Landi, S.
Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma	1-gen-2012	Pinton, G.; Manente, A. G.; Angeli, G.; Mutti, L.; Moro, L.
Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma (PLoS ONE (2017) 12:6 (e0180317) DOI: 10.1371/journal.pone.0085935)	1-gen-2017	Melaiu, O.; Stebbing, J.; Lombardo, Y.; Bracci, E.; Uehara, N.; Bonotti, A.; Cristaudo, A.; Foddis, R.; Mutti, L.; Barale, R.; Gemignani, F.; Giamas, G.; Landi, S.
Evaluation of the role of p53 tumour suppressor posttranslational modifications and ttc5cofactor in lung cancer	1-gen-2021	Alhebshi, H.; Tian, K.; Patnaik, L.; Taylor, R.; Bezecny, P.; Hall, C.; Muller, P. A. J.; Safari, N.; Creamer, D. P. M.; Demonacos, C.; Mutti, L.; Bittar, M. N.; Krstic-demonacos, M.
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells	1-gen-2017	Pattarozzi, A.; Carra, E.; Favoni, R. E.; Wurth, R.; Marubbi, D.; Filiberti, R. A.; Mutti, L.; Florio, T.; Barbieri, F.; Daga, A.
BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment	1-gen-2019	Guazzelli, A.; Meysami, P.; Bakker, E.; Demonacos, C.; Giordano, A.; Krstic-Demonacos, M.; Mutti, L.
Targeting hypoxic response for cancer therapy	1-gen-2016	Paolicchi, E.; Gemignani, F.; Krstic-Demonacos, M.; Dedhar, S.; Mutti, L.; Landi, S.
Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo	1-gen-2013	Manente, A. G.; Valenti, D.; Pinton, G.; Jithesh, P. V.; Daga, A.; Rossi, L.; Gray, S. G.; O'Byrne, K. J.; Fennell, D. A.; Vacca, R. A.; Nilsson, S.; Mutti, L.; Moro, L.
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals	1-gen-2017	De Santi, C.; Pucci, P.; Bonotti, A.; Melaiu, O.; Cipollini, M.; Silvestri, R.; Vymetalkova, V.; Barone, E.; Paolicchi, E.; Corrado, A.; Lepori, I.; Dell'Anno, I.; Pelle, L.; Vodicka, P.; Mutti, L.; Foddis, R.; Cristaudo, A.; Gemignani, F.; Landi, S.
The biochemical role of the human NEIL1 and NEIL3 DNA glycosylases on model DNA replication forks	1-gen-2019	Albelazi, M. S.; Martin, P. R.; Mohammed, S.; Mutti, L.; Parsons, J. L.; Elder, R. H.
Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state	1-gen-2020	Alhammad, R.; Khunchai, S.; Tongmuang, N.; Limjindaporn, T.; Yenchitsomanus, P. -T.; Mutti, L.; Krstic-Demonacos, M.; Demonacos, C.

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 4.601 a 4.620 di 38.799

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext27069
open8257
restricted2454
reserved922
partially open90
mixed4
embargoed3